847799-64-8

Usage

Uses

Used in Pharmaceutical Synthesis:
2-bromo-N-methylpyridin-4-amine is used as an intermediate in the synthesis of pharmaceuticals for its unique reactivity and properties. It plays a crucial role in the development of new drugs and contributes to the advancement of medicinal chemistry.
Used in Agrochemical Production:
In the agrochemical industry, 2-bromo-N-methylpyridin-4-amine is utilized as an intermediate in the production of various agrochemicals. Its unique properties make it suitable for the synthesis of compounds that can be used in crop protection and other agricultural applications.
Used in Dye and Pigment Manufacturing:
2-bromo-N-methylpyridin-4-amine is also employed in the manufacturing of dyes and pigments due to its aromatic amine nature. Its presence in the structure of these compounds contributes to their color and stability, making it an essential component in the production of various dyes and pigments.
Used in Organic Chemistry Research:
As a compound with unique reactivity and properties, 2-bromo-N-methylpyridin-4-amine is commonly studied and utilized in laboratory settings. It serves as a valuable research tool for chemists to explore new reactions, mechanisms, and applications in the field of organic chemistry.

Upstream product

• 7598-35-8 2-bromo-4-aminopyridine 
• 13061-96-6 dihydroxy-methyl-borane 
• 74-88-4 methyl iodide 
• 357927-50-5 2-bromo-4-fluoro-pyridine 
• 74-89-5 methylamine 

Relevant academic research and scientific papers

BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF

The present disclosure provides bifunctional compounds as IRAK4 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by IRAK4.

BENZOSULFONYL COMPOUNDS

Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.

Structure-Activity Relationships of Radioiodinated Benzoimidazopyridine Derivatives for Detection of Tau Pathology

It is generally accepted that neurofibrillary tangles consisting of tau proteins are involved in the pathogenesis of Alzheimer's disease (AD). For selective detection of tau pathology, we synthesized and evaluated radioiodinated benzoimidazopyridine (BIP) derivatives with an alkylamino group as tau imaging probes. In vitro selectivity to tau aggregates and in vivo pharmacokinetics of BIP derivatives varied markedly, being strongly dependent on the alkylamino group. In in vitro autoradiography with AD brain sections, the BIP derivative with a dimethylamino group (BIP-NMe2) showed the highest selectivity to tau aggregates. Regarding the biodistribution using normal mice, the BIP derivative with an ethylamino group (BIP-NHEt) showed the highest uptake (6.04% ID/g at 2 min postinjection) into and rapid washout (0.12% ID/g at 60 min postinjection) from the brain. These results suggest that the introduction of an optimal alkylamino group into the BIP scaffold may lead to the development of more potential tau imaging probes.

Kinetic analyses and structure-activity relationship studies of synthetic lysine acetylation catalysts

Lysine acylation of proteins is a crucial chemical reaction, both as a post-translational modification and as a method for bioconjugation. We previously developed a chemical catalyst, DSH, which activates a chemically stable thioester including acyl-CoA, allowing the site-selective lysine acylation of histones under physiological conditions. However, a more active catalyst is required for efficient lysine acylation in more complex biological milieu, such as in living cells, but there are no rational guidelines for developing efficient lysine acylation catalysts for use under physiological conditions as opposed to in organic solvents. We, herein, conducted a kinetic analysis of the ability of DSH and several derivatives to mediate lysine acetylation to better understand the structural elements essential for high acetylation activity under physiological conditions. Interestingly, the obtained trend in reactivity was different from that observed in organic solvents, suggesting that a different principle is necessary for designing chemical catalysts specifically for use under physiological conditions compared to catalysts for use in organic solvents. Based on the obtained information, we identified a new catalyst scaffold with high activity and structural flexibility for further modification to improve this catalyst system.

AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS

The present disclosure relates to amine-substituted aryl or heteroaryl compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., sickle cell anemia) via inhibition of a methyltransferase enzyme selected from EHMT1 and EHMT2, by administering an amine-substituted aryl or heteroaryl compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.